康方生物依沃西再次头对头战胜PD1单抗,有望成为下一代免疫治疗的基石药物

国信证券
24 Apr

事项:公司公告:依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的3期头对头临床试验期中分析显示强阳性结果:达到PFS的主要临床终点,具有统计学显著意义和重大临床获益。国信医药观点:1)这是依沃西在NSCLC取得的第三项显著阳性结果的3期临床,也是第二项头对头PD1疗法获得阳性结果的3期临床,依沃西联合化疗突破了贝伐珠单抗无法应用sqNSCLC的瓶颈,有望成为新的一线标准疗法;2...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10